-transparent.png){kind=logo}
A newly developed cephalosporin, cefteram pivoxil (CFTM-PI, T-2588), was evaluated clinically in 40 patients. A pharmacokinetic study was also performed with 8 patients. CFTM-PI was administered as granules. One patient was given CFTM-PI at a dose of 1.5 mg/kg, each of 3 patients was given the drug at a dose of 3 mg/kg and each of 4 patients at a dose of 6 mg/kg. In most cases, serum concentrations of CFTM were determined at 2, 3, 4, and 6 hours after dosing. Urinary concentrations of CFTM were measured for urinary samples collected during periods of 0-2, 2-4, 4-6 and 6-8 hours after dosing. CFTM was assayed using the disk or the cup method using Klebsiella pneumoniae ATCC 10031 as the test organism. The clinical evaluation was conducted in 40 children including 13 patients of acute tonsillitis, 10 of acute lacunar tonsillitis, 10 of scarlet fever, 2 of acute bronchitis, 2 of pneumonia, and 1 each of pneumonia with enteritis, phlegmon and urinary tract infection. The patients were from 4 months to 13 years old. Daily doses were from 8.7 to 12 mg/kg. After CFTM-PI administration in doses 1.5 mg/kg, 3 mg/kg and 6 mg/kg, peak serum concentrations of CFTM were 0.38 microgram/ml, 0.73-2.25 micrograms/ml and 1.2-2.9 micrograms/ml, respectively, and half-lives were 1.55, 0.95-2.30 and 0.80-2.72 hours, respectively. Urinary excretion rates up to 6 or 8 hours after dosing were 10.8-24.7%. Clinical efficacies of CFTM-PI in 40 patients were "excellent" in 27 children, "good" in 12 children and "fair" in 1 with an efficacy rate of 97.5%. Twenty seven strains of causative organisms, including 15 strains of Streptococcus pyogenes, 1 of Escherichia coli, 1 of Salmonella 04, 6 of Haemophilus influenzae, 1 of Haemophilus parainfluenzae and 3 of Branhamella catarrhalis, were isolated. After treatment all strains except 1 strain of B. catarrhalis (unchanged), Salmonella 04 (unknown) and 1 strain of H. parainfluenzae (unknown) were eradicated. Side effects observed clinically were only 1 case of diarrhea. Eosinophilia was observed in 1 case.
H Sato, and
A Narita, and
S Nakazawa, and
H Suzuki, and
K Matsumoto, and
Y Nakanishi, and
K Niino, and
S Nakazawa
August 1989,
The Japanese journal of antibiotics,
H Sato, and
A Narita, and
S Nakazawa, and
H Suzuki, and
K Matsumoto, and
Y Nakanishi, and
K Niino, and
S Nakazawa
September 1989,
The Japanese journal of antibiotics,
H Sato, and
A Narita, and
S Nakazawa, and
H Suzuki, and
K Matsumoto, and
Y Nakanishi, and
K Niino, and
S Nakazawa
August 1989,
The Japanese journal of antibiotics,
H Sato, and
A Narita, and
S Nakazawa, and
H Suzuki, and
K Matsumoto, and
Y Nakanishi, and
K Niino, and
S Nakazawa
August 1989,
The Japanese journal of antibiotics,
H Sato, and
A Narita, and
S Nakazawa, and
H Suzuki, and
K Matsumoto, and
Y Nakanishi, and
K Niino, and
S Nakazawa
August 1989,
The Japanese journal of antibiotics,
H Sato, and
A Narita, and
S Nakazawa, and
H Suzuki, and
K Matsumoto, and
Y Nakanishi, and
K Niino, and
S Nakazawa
August 1989,
The Japanese journal of antibiotics,
H Sato, and
A Narita, and
S Nakazawa, and
H Suzuki, and
K Matsumoto, and
Y Nakanishi, and
K Niino, and
S Nakazawa
September 1989,
The Japanese journal of antibiotics,
H Sato, and
A Narita, and
S Nakazawa, and
H Suzuki, and
K Matsumoto, and
Y Nakanishi, and
K Niino, and
S Nakazawa
August 1989,
The Japanese journal of antibiotics,
H Sato, and
A Narita, and
S Nakazawa, and
H Suzuki, and
K Matsumoto, and
Y Nakanishi, and
K Niino, and
S Nakazawa
September 1989,
The Japanese journal of antibiotics,
H Sato, and
A Narita, and
S Nakazawa, and
H Suzuki, and
K Matsumoto, and
Y Nakanishi, and
K Niino, and
S Nakazawa
September 1989,
The Japanese journal of antibiotics,
